GRTS News and Press, Gritstone Oncology Inc. From 05/09/24

2024-05-09 16:26:03 ET More on Gritstone bio Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering Gritstone stock plunges 35% amid Phase 2 data, public offering Gritstone announces proposed public offering Seeking Alpha’s Quant Rating on...

-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial result...

-- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the majority of participants studied, including those living with HIV, after administration of a...

EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive i...

-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS...

-- State-of-the-art neoantigen prediction platform (EDGE ™ ) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly...

2024-04-07 00:22:19 ET Summary Gritstone bio's GRANITE program shows promising preliminary results in the treatment of metastatic microsatellite stable colorectal cancer (MSS-CRC). The data suggests that GRANITE could be an innovative treatment for MSS-CRC and potentially other on...

NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS). Investors who purchased Gritstone securities are encouraged to obtain additional infor...